Ingrid E. Wertz is the Executive Director of the Protein Homeostasis Center of Excellence at Bristol Myers Squibb and was previously a Principal Scientist at Genentech, where she co-initiated and led the Genentech Degrader Platform. She obtained her undergraduate degree in Molecular and Cellular Biology from the University of California at Berkeley, performed her graduate studies at Genentech via an NIH Biotechnology Training Grant from U.C. Davis, and received her M.D. from Washington University in St. Louis as a Medical Scientist Training Program fellow. Dr. Wertz’s research is primarily focused on co-opting the Ubiquitin System for therapeutic benefit.
